BioCentury

8:00 AM GMT, Nov 17, 2008
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Ganging up on HCV

There has long been agreement in the clinical community that in certain diseases it would make sense to test two unapproved compounds together rather than adding each separately to an approved regimen and waiting to combine them until at least one reaches the market. But the regulatory pitfalls of proving which compound contributes what degree of efficacy and side effects have discouraged such efforts.

A case in point is HCV, in which combining several compounds with the potential to block multiple aspects of viral replication ultimately could supplant the suboptimal interferon-based standard of care.

Despite a lack of regulatory clarity from FDA

Read the full 1009 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.